reference/5902633

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/5902633

Outgoing Links

Predicate	Object
contentType	Clinical Trial, Phase II\|Journal Article\|Multicenter Study\|Randomized Controlled Trial\|Research Support, Non-U.S. Gov't
endingPage	831
issn	0167-6806 1573-7217
issueIdentifier	3
pageRange	819-831
publicationName	Breast Cancer Research and Treatment
startingPage	819
bibliographicCitation	Marmé F, Werft W, Walter A, Keller S, Wang X, Benner A, Burwinkel B, Sinn P, Hug S, Sohn C, Bretz N, Moldenhauer G, Rupp C, Rupp AK, Biakhov MY, Bottini A, Friedrichs K, Khailenko VA, Manikhas GM, Ruiz A, Sánchez-Rovira P, Santoro A, Segui MA, Villena C, Lichter P, Kristiansen G, Altevogt P, Schneeweiss A. CD24 Ala57Val polymorphism predicts pathologic complete response to sequential anthracycline- and taxane-based neoadjuvant chemotherapy for primary breast cancer. Breast Cancer Res Treat. 2012 Apr;132(3):819–31. doi: 10.1007/s10549-011-1759-9. PMID: 21960110.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_bc79616e4181c8965c675e210659610b http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_416733021f9d21e0745cf7b996f1fec0 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_499aaf5cff7ea8e5d69cc7c0c5c1240c http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_28928ecf0e94d1e7cfd4e6591da9065a http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_24a154be39a65793659a10e9cdf65df7 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c1d50a65e0183bbbb3fdc90fb25b2d6c http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_efa3738c1089f76be382714a7ecb4106 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a20bbf974ad321e458e9d75c6692ece1 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_dba6deb20d103d623308dc5ae333570b http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2ba99ed5cf7167c967c09a89b56e62a2 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_fa37cfa48e4a2643c7293e02b0b64086 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_97ade3635c5ccd9af2c1405d3060a1e2 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_625a77675db49e86d41f10d55549dd95 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_efc26f61a49dfca5e8f5ecdbf4e03964 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_207c87914717455fbfd1feb4cec7c787 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_553efe0abd981db16eaa08d261456395 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_7b7c761ea7d7c64981307d17187d149c http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0fda30e1a07805fed47202e3ca241779 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_605c00dcb1ec563a00f32d972528c0bf http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8d85142f4140316aee760c2cbc315a3f http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_6fc905564005c57cb0d3610112e8248b http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_39fcccb577372d10c612d8f04c380bbd http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_cbe4ffb4899d37e8504745739fcd73da http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a32889226cd7113f0098af98a5809b9c http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b3de64a781bf869ff9790aa5590cfaa7 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_eb2c68cfadf2fe396a1a52fd496b45a6 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1ecb340632cfd6a8d4f555e1a72b89d9 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_7a02a8f5aa763859402c3068ee285b50
date	2011-09-30-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://doi.org/10.1007/s10549-011-1759-9 https://pubmed.ncbi.nlm.nih.gov/21960110
isPartOf	https://portal.issn.org/resource/ISSN/1573-7217 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/1254 https://portal.issn.org/resource/ISSN/0167-6806
language	English
source	https://www.crossref.org/ https://scigraph.springernature.com/ https://pubmed.ncbi.nlm.nih.gov/
title	CD24 Ala57Val polymorphism predicts pathologic complete response to sequential anthracycline- and taxane-based neoadjuvant chemotherapy for primary breast cancer
discusses	http://id.nlm.nih.gov/mesh/M0006784 http://id.nlm.nih.gov/mesh/M0172384 http://id.nlm.nih.gov/mesh/M0184558 http://id.nlm.nih.gov/mesh/M0472258 http://id.nlm.nih.gov/mesh/M0009376 http://id.nlm.nih.gov/mesh/M0009679 http://id.nlm.nih.gov/mesh/M0005485 http://id.nlm.nih.gov/mesh/M0026536 http://id.nlm.nih.gov/mesh/M0227083 http://id.nlm.nih.gov/mesh/M0506275 http://id.nlm.nih.gov/mesh/M0443608
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID148124 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5950 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8607 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_aa6ccad54bf22b1b81ce5a3c6d0ae839 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2907 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7102 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID30323 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7001 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID31703 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID9548828 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID135410875 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID602 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6287

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID135945851 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129439837 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129159660

Total number of triples: 75.